PepGen Inc. PEPG
Set alert
2.36 USD -0.05 -2.07%
At close · Oct 30
2.41 +0.05 +2.12%
After hours · Oct 30, 7:49 PM ET
2.22 Day range 2.41
1.35 52-week range 7.17
- YTD
- -63.75%
- 1 year
- -47.90%
- Open
- 2.40
- Prev close
- 2.41
- Mkt cap
- 163.24M
- Vol
- 1.13M
- Avg vol
- 938.28K
- EPS
- -1.01
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.22
- High
- 2.41
- Forward P/E
- -1.45
- Beta
- 1.76
- Short ratio
- 5.75
- Inst. own
- 96.36%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 6.03
- 200-d avg
- 11.24
- 1y target
- 15.40
Key statistics
- Market cap
- 126.80M
- Enterprise value
- -1.49M
- Trailing P/E
- 0.00
- Forward P/E
- -1.45
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.92
- EPS (TTM)
- -2.98
- Beta
- 1.76
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -52.01M
- Total cash
- 138.86M
- Total debt
- 19.04M
- Return on equity
- -66.26%
- Shares outstanding
- 32.60M
- Short % of float
- 4.52%
- 50-day average
- 6.03
- 200-day average
- 11.24
Analyst view
Consensus: buy
Buy
Price target (mean) 15.40 +552.5% upside
Now 2.36
- Target (low)
- 6.00
- Target (mean)
- 15.40
- Target (high)
- 26.00
Ratings (0m) 5 4 buy · 1 hold · 0 sell
- Strong buy1
- Buy3
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.72.
Financials — quick view
PEPG Revenue — quarterly 0
PEPG Net income — quarterly -17.81M
PEPG EPS — quarterly -0.26
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.87 | -0.66 | +0.21 | +24.14% |
| Aug 8, 2024 | Jun 1, 2024 | -0.72 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.72 | -0.87 | -0.15 | -20.83% |
| May 14, 2024 | Mar 1, 2024 | -0.74 | -0.63 | +0.11 | +14.86% |
| May 14, 2024 | Mar 1, 2024 | -0.74 | — | — | — |
| Mar 6, 2024 | Dec 1, 2023 | -1.01 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2024 | B of A Securities | main | Neutral | Neutral |
| Nov 8, 2024 | Wedbush | main | Outperform | Outperform |
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 31, 2024 | Wedbush | reit | Outperform | Outperform |
| May 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- pepgen.com
News
- PepGen, Inc. (NASDAQ:PEPG) Stock Now Rated “Moderate Buy” by Wall Street Analysts
- PepGen, Inc. $PEPG Shares Bought by Squarepoint Ops LLC
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- HC Wainwright & Co. Reiterates Buy on PepGen, Maintains $20 Price Target
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- ADAR1 Capital Management LLC Acquires New Shares in PepGen, Inc. $PEPG
- PepGen Q2 EPS $(0.26) Beats $(0.29) Estimate
- PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
- PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
- PepGen Receives Recommendation To Advance its Phase 2 FREEDOM2-DM1 Study Of PGN-EDODM1 In Participants With Myotonic Dystrophy Type 1 Into The Highest Dose Cohort
Your note
Sign in to keep a note on PEPG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GOYAL JAYA | Officer | Sale | Mar 23, 2023 | 0 |
| MCARTHUR JAMES G PH.D. | Chief Executive Officer | Purchase | Nov 29, 2023 | 1,694 |
| MELLION MICHELLE L | Officer | Sale | Jul 24, 2024 | 0 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 8, 2024 | 0 |
| SVENSTRUP NIELS | Officer | Sale | May 16, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 32.79% | 10,689,545 | 41.58M | Sep 29, 2024 |
| Janus Henderson Group PLC | 7.17% | 2,336,516 | 9.09M | Sep 29, 2024 |
| Suvretta Capital Management, LLC | 5.10% | 1,660,932 | 6.46M | Sep 29, 2024 |
| Viking Global Investors, L.P. | 4.55% | 1,482,434 | 5.77M | Sep 29, 2024 |
| Perceptive Advisors Llc | 4.33% | 1,410,438 | 5.49M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 3.46% | 1,127,536 | 4.39M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.51% | 492,801 | 1.92M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.22% | 396,779 | 1.54M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.89% | 289,477 | 1.13M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.49% | 158,985 | 618.45K | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.37% | 120,157 | 467.41K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.29% | 95,295 | 370.70K | Oct 30, 2024 |